Viral Core Proteins

• 

  Subject Areas on Research

  • A highly sensitive and specific enzyme-linked immunosorbent assay of antibodies to hepatitis C virus. 
  • A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. 
  • C-terminal region of human T cell lymphotropic virus type I (HTLVI) p19 core protein is immunogenic in humans and contains an HTLVI-specific epitope. 
  • Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. 
  • Conservation of the 3' terminal nucleotide sequences of Ebola and Marburg virus. 
  • Domain 3 of hepatitis C virus core protein is sufficient for intracellular lipid accumulation. 
  • Efficient and specific gene knockdown by small interfering RNAs produced in bacteria. 
  • Generation of reovirus core-like particles in cells infected with hybrid vaccinia viruses that express genome segments L1, L2, L3, and S2. 
  • Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice. 
  • Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS) 
  • Measuring Hepatitis C Virus Envelopment by Using a Proteinase K Protection Assay. 
  • Monoclonal antibodies against human T cell leukemia-lymphoma virus (HTLV) p24 internal core protein. Use as diagnostic probes and cellular localization of HTLV. 
  • Monoclonal antibodies reactive with human T cell lymphotropic virusI (HTLVI) p19 internal core protein: cross-reactivity with normal tissues and differential reactivity with HTLV types I and II. 
  • Rapid inhibition of processing and assembly of small nuclear ribonucleoproteins after infection with vesicular stomatitis virus. 
  • Rotavirus RNA polymerase requires the core shell protein to synthesize the double-stranded RNA genome. 
  • Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. 
  • The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-1) infected individuals. 
  • The interaction of a series of hybridoma IgGs with reovirus particles. Demonstration that the core protein lambda 2 is exposed on the particle surface. 
  • The sequence of the reovirus serotype 3 L3 genome segment which encodes the major core protein lambda 1. 
  • The sequences of reovirus serotype 3 genome segments M1 and M3 encoding the minor protein mu 2 and the major nonstructural protein mu NS, respectively. 
  • Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.